Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/13/2010CN101254243B Apply externally powder for curing gland hyperplasia
10/13/2010CN101245081B Novel cephalosporin derivative
10/13/2010CN101244247B Pharmaceutical combination for treating cervical vertebra disease and waist and leg pain, and preparation thereof
10/13/2010CN101244151B Medicament for treating dysentery
10/13/2010CN101234112B New purpose of cation carbazoles compounds
10/13/2010CN101219144B Long-circulation nano-grain of hydroxycamptothecin and method for preparing the same
10/13/2010CN101214346B Chinese medicine emplastrum for treating pain of vertebrae cervicables lumbar intervertebral disc
10/13/2010CN101205538B Clone, expression and use of Schistosoma Japonicum signal transduction protein Sjwnt-4 gene
10/13/2010CN101194990B Chinese medicine ointment for treating ache of neck, shoulder, waist and leg
10/13/2010CN101190197B Praziquantel chewable tablets for dog or cat
10/13/2010CN101180047B Use of cyclodextrin complexes containing lipoic acid
10/13/2010CN101167879B Preparation for increasing erection rigidity and prolonging intercourse endurance and condom containing the same
10/13/2010CN101157715B Ursolic acid chemical modified compound amino alcohol having antitumor activity
10/13/2010CN101152170B Capsule containing pseudoephedrine and method for preparing the same
10/13/2010CN101138555B Application of octacosanol in the preparation of medicament for treating and preventing hypoxic pulmonary hypertension
10/13/2010CN101133036B Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS)
10/13/2010CN101121696B Metal salt of pyritinol and hydrate of the same
10/13/2010CN101107249B Purine derivatives acting as a2a receptor agonists
10/13/2010CN101104609B Solanesyl polyamine derivative, preparation and application thereof
10/13/2010CN101103030B Medicaments with HM74A receptor activity
10/13/2010CN101099738B Application of sanguinarine in preparing aquatic animal medicine and method for preparing its preparation
10/13/2010CN101095693B Compound recipe medicine for treating dermatitis
10/13/2010CN101088507B Application of ophiopogoni D in preparing gene medicine for regulating vasular endothelial cell period
10/13/2010CN101087604B Medicaments for the treatment or prevention of fibrotic diseases
10/13/2010CN101084217B Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds
10/13/2010CN101081843B Non-nucleoside reverse transcriptase inhibitors
10/13/2010CN101073564B Medicinal composition containing L-glutamine
10/13/2010CN101054372B Pyrimidine substituted benzenepropanoic acid derivative, its preparation method and use in curing polycystic kidney disease
10/13/2010CN101041629B New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
10/13/2010CN101039671B Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
10/13/2010CN101035765B Sulfonamide derivatives
10/13/2010CN101019869B Medicine composition of alprostadil and Chuanhuning/Yanhuning liposome and its preparation
10/13/2010CN101007014B A compound puerarin preparation
10/12/2010US7812178 such as (R)-3-(3-hydroxypyrrolidin-1-yl)-N-methyl-N-methoxypropanamide; poly(ADP-ribose)polymerase inhibitors
10/12/2010US7812177 Potassium channel opener having benzofuroindole skeleton
10/12/2010US7812176 reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators
10/12/2010US7812174 Methods of preparing imidazole-based compounds
10/12/2010US7812169 Angiogenesis inhibitors; vision defects; anticancer agents; retinopathy; skin disorders; antiarthritic agents; antitumor agents; aids
10/12/2010US7812167 Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
10/12/2010US7812165 6-substituted pyridoindolone derivatives, production and therapeutic use thereof
10/12/2010US7812162 Enantiomers of 2′-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics
10/12/2010US7812160 G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases
10/12/2010US7812159 Processes for preparing aromatic ethers
10/12/2010US7812152 Amphiphilic cyclodextrin derivatives, method for preparation thereof and uses thereof
10/12/2010US7812151 Low molecular weight polysaccharides having antithrombotic activity
10/12/2010US7812148 Vectors comprising CpG islands without position effect varigation and having increased expression
10/12/2010US7812142 Pentose derivatives as anti-hyperglycemic drugs
10/12/2010US7812136 useful for monitoring the (de)activation status if the patient is treated with thrombocyte aggregation inhibitors
10/12/2010US7812058 Use of apogossypol derivatives to treat cancer; drug screening for Bcl-2 protein inhibitors
10/12/2010US7812057 Cosmetic compositions
10/12/2010US7812056 Polycondensate esters from ditrimethylolpropane, polyvalent carboxylic acids, and fatty acids; improved dispersability, heat resistance, smell and color
10/12/2010US7812054 administering methyl (E,5S,6R)-5,6-dihydroxy-8-[2-[(E,3R)-3-hydroxyoct-1-enyl]phenyl]oct-7-enoate, optionally with a cyclooxygenase inhibitor selected from celecoxib, rofecoxib, and valdecoxib, to humans or animals for the treatment of an oral inflammation
10/12/2010US7812053 Peroxisome proliferator activated receptor moderators; dyslipidemia; anticholesterol agents ; antidiabetic agents; hypotensive agents; antiischemic agents
10/12/2010US7812052 Stable aqueous formulation of a platin derivative
10/12/2010US7812051 conjugated to polyglutamic acid for enhanced permeability and retention effect
10/12/2010US7812050 Characterized crystalline form and having an x-ray powder diffraction peak at 2 theta=11.0 degrees, using Cu K-alpha radiation; spectrum analysis; solubility; treatment for medical, psychiatric and/or neurological condition or disorder; stability lower dosage; side effect reduction; Tyrima (C157)
10/12/2010US7812049 alpha 1-adrenoceptor agonists for treating skin redness; oxymetazoline hydrochloride
10/12/2010US7812048 N-[3-[(2S)-1-methoxypropan-2-yl]oxy-5-(4-methylsulfonylphenoxy)phenyl]-1H-imidazole-5-carboxamide, used as antidiabetic agents, especially for the treatment of non-insulin dependent diabetes
10/12/2010US7812047 4-imidazolines
10/12/2010US7812046 Administerin mixture of peroxisome proliferator activated receptor and angiotensin receptor antagonist; antidiabetic agents
10/12/2010US7812045 1-(5-(4-trifluoromethyl-benzylamino)-1H-indazol-1-yl)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol; 2-(2,4-difluorophenyl)-1-(1H-indazol-1-yl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol
10/12/2010US7812044 Hormone sensitive vcancer; antiproliferative agents ; induction apoptosis; angiotensin inhibitors
10/12/2010US7812043 {2-[(1-cyclopropylmethyl-6-fluoro-1H-indole-3-carbonyl)-amino]-thiazol-5-ylsulfanyl}-acetic acid, used for treating non-insulin dependent diabetes, dyslipidemia, hyperlipidemia, hypertension, obesity and as dietetics
10/12/2010US7812042 novel synthetic thiolatocobalamin; protects animal cells against oxidative stress damage; dietary supplement; also with vitamin B6 and a folate; cardiovascular disease, cerebrovascular disease, peripheral vascular disease, glaucoma, Alzheimer's disease, and dementia
10/12/2010US7812041 such as 2-Morpholin-4-yl-thiazole-4-carboxylic acid (5,6-dimethyl-1H-benzoimidazol-2-yl)-amide, used for the treatment of dementia, amyotrophic lateral sclerosis, stroke, epilepsy, multiple sclerosis, myasthenia gravis, Huntington's, Alzheimer's, Parkinson's, Meniere's and Creutzfeld-Jacob Disease
10/12/2010US7812040 Histamine-3 receptor antagonists
10/12/2010US7812039 analgesic drug for treating neuropathic pain is selected from gabapentine, norvaline, pregabaline, (S)3-isobutylGABA, arginine, thiocitrulline, agmantine, vigabatrin etc. and a NO donar drugs belonging to the classes of aspirin, ibuprofen, paracetamol, naproxen, diclofenac or flurbiprofen
10/12/2010US7812038 such as vascular cell adhesion molecules and fibronectins, administered for the treatment of asthma, multiple sclerosis or inflammatory bowel diseases in mammals; (3S)-3-{[({1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3quinolinyl}amino)carbonyl]amino}-3-(4-methylphenyl)propanoic acid
10/12/2010US7812037 such as 4-{4-fluoromethyl-2-methyl-5-[(4-carbamimidoyl-benzyloxy)-methyl]-pyridin-3-yloxymethyl}-benzamidine, that inhibit the proteases of the blood and thus block platelet aggregation, used for the treatment of cardiovascular disorders
10/12/2010US7812036 Androgens
10/12/2010US7812035 Psychological disorders; antidepressants; anxiolytic agents; sexual disorders
10/12/2010US7812034 Using HIV protease inhibitors (indinavir, nelfinavir, ritonavir, or saquinavir) alone or in combination with chemotherapy, radiotherapy, or surgery
10/12/2010US7812033 Method for increasing the activity of acid-β-galactosidase
10/12/2010US7812032 crystalline forms of zotarolimus (ABT-578); bioavailability, solubility
10/12/2010US7812031 Pyrimidine derivatives as orexin receptor antagonists
10/12/2010US7812030 Methods, compositions, and kits for organ protection during systemic anticancer therapy
10/12/2010US7812029 such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis
10/12/2010US7812028 3-pyridinecarboxamide derivatives as HDL-cholesterol raising agents
10/12/2010US7812027 antidiabetic agents such as (2R,3S,5R)-5-[2-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-2-(2,4,5-trifluorophenyl)tetrahydro-2H-pyran-3-amine; non-insulin dependent diabetes
10/12/2010US7812026 Imidazole derivatives having a positive allosteric GABAB receptor modulator effect and methods of use
10/12/2010US7812025 neuroprotectants such as 4-biphenyl-3-yl-N-pyridin-3-ylpiperazine-1-carboxamide effective in prevention and treatment of cerebrovascular disorders such as necrosis, hemorrhages, injuries, as antidepressants and/or anxiolytic agents
10/12/2010US7812024 such as (4R,11aR)-4-methyl-1,2,3,4,11,11a-hexahydropyrazino[1,2-b]isoquinolin-6-one, used for the treatment of obesity, diabetes, atherosclerosis, dyslipidemia, anxiety, depression, psychosis, schizophrenia, sleep, sexual, obsessive compulsive and gastrointestinal disorders
10/12/2010US7812023 Methods of using substituted morpholine derivatives
10/12/2010US7812022 protein tyrosine kinase inhibitors such as 2,6-Difluoro-N-[3-(3-{2-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl)phenyl]benzamide, used as anticarcinogenic or antitumor agents
10/12/2010US7812021 {(3RS,4SR)-3-(3,4-dichloro-phenyl)-4-[(RS)-1-(4-trifluoromethyl-phenoxy)-ethyl]-pyrrolidin-1-yl}-(4-methanesulfonyl-piperazin-1-yl)-methanone, for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder
10/12/2010US7812020 Substituted pyridine derivatives
10/12/2010US7812019 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
10/12/2010US7812018 inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer
10/12/2010US7812017 such as 1-(Phenylsulfonyl)-4-(piperazin-1-ylmethyl)-1H- indole, hydrochloride, used as dietetics, selective serotonin receptor antagonists or in cosmetics
10/12/2010US7812016 HIV integrase inhibitors such as 5-(1,1-Dioxido-1,2-thiazinan-2-yl)-7[5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl]-1,6-naphthyridin-8-ol, useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC
10/12/2010US7812015 Using tricyclic or tetracyclic antidepressant amitryptiline, imipramine, desipramine or FGF as inhibitors of acid sphingomyelinase which liberates ceramide, for prophylaxis and/or treatment of infectious diseases ( AIDS, hepatitis A, tuberculosis, rubella, SSME, influenza, rhinoviral diseases, malaria)
10/12/2010US7812014 such as (5R,6Z)-6-[(5-benzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)methylene]-7oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, in combination with beta-lactam antibiotics, for the treatment of bacterial infections
10/12/2010US7812013 4-Imino-2-methyl-3,5,13-triazatetracyclo[15.3.1.1(2,5).1(7,11)]tricosa-1(21),7,9,11(22),17,19-hexaene-12,23-dione, used for treating cardiovascular diseases, cognitive and neurodegenerative diseases
10/12/2010US7812011 Farnesoid X receptor (FXR) agonists comprising 3-alpha ,7-beta-dihydroxy-6 alpha-ethyl-5 beta-cholan-24-oic acid, salts, solvates or amino acid conjugates, used for the treatment of hyperlipemiaa, hypercholesterolemia, hypertriglyceridemia, atherosclerosis and for increasing high density lipoproteins
10/12/2010US7812010 Pharmaceutical preparations for treatments of diseases and disorders of the breast
10/12/2010US7812009 Mastitis treatment
10/12/2010US7812008 such as (4S,4aS,5aR,12aS)-9-[(N-cyclohexyl-N-hydroxyglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide, useful as antimicrobial agents and exhibit antibacterial activity against a wide spectrum of microorganisms
10/12/2010US7812007 Preventing proliferation of smooth muscle cells and/or angiogenesis; selective activity towards activated factor X and/or II
10/12/2010US7812006 Conjugates obtained by reductive amination of the pneumococcus serotype 5 capsular polysaccharide
10/12/2010US7812005 Glycosaminoglycans correct emotional dysfunctions without altering the normal state of consciousness, because of their ability to prevent or reduce the alteration (fluidity)of the extracellular matrix (ECM) in the brain; depolymerized sulfates of dermatan, chondroitin, heparin, keratin; psychosis
1 ... 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 ... 7860